First and only FDA-approved treatment to target an impaired MC4R pathway, a fundamental cause of hunger and obesity in individuals with BBS, or POMC, PCSK1, or LEPR deficiency. This evidence concerns the gene POMC and Bardet-Biedl syndrome.